A randomized controlled trial of Roxadustat in anemia of cirrhosis of liver and it's effects on HIF-1-alpha level.
Phase 2
- Conditions
- AnemiaAnemia in patients with Cirrhosis of liver Effects of Roxadustat in correcting anemia in cirrhosis.Cirrhosis of LiverRoxadustatHIF-1-alphaEPO level
- Registration Number
- TCTR20230619004
- Lead Sponsor
- Bangabandhu Seikh Mujib Medical University,Shahbag, Dhaka-1000,Bangladesh
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- All
- Target Recruitment
- 105
Inclusion Criteria
1. Patients with cirrhosis of liver (Child pugh A or B)
2. Haemoglobin level > 7 gm/dl.
3. Age: 18 to 60 years.
Exclusion Criteria
1. Patients with Child Pugh C liver cirrhosis
2. Haemoglobin level <7 gm/dl
3. Hepatocellular carcinoma
4. Pregnancy
5. Active variceal bleeding
6. Adult polycystic kidney disease
7. Hypo/Hyperthyroidism
8. Systemic Hypertension
9. Hyperkalemia
10. Patient with co-morbid condition (COPD, CKD, CCF, MI etc.)
11. Anemia caused by other haematological disorder associated with cirrhosis of liver.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method